冠心病患者血浆尾加压素Ⅱ的临床研究

南方医科大学学报 ›› 2004, Vol. 24 ›› Issue (05): 563-565.

冠心病患者血浆尾加压素Ⅱ的临床研究

方石虎¹, 李志樑¹, 吴宏超¹, 唐朝枢², 陆青¹, 刘海潮¹, 严全能¹

1. 第一军医大学珠江医院心血管内科, 广东, 广州, 510282;
2. 北京大学第一医院心血管研究所, 北京, 100034

出版日期:2004-05-20 发布日期:2004-05-20
基金资助:
收稿日期:2003-12-7。
基金项目:国家重大基础发展研究项目(973子课题;G200056905)
作者简介:方石虎(1975- ),男,1998年毕业于江西医学院,现为第一军医大学在读硕士研究生,电话:020-61643160,E-mail:fshjxjj@163.com

Clinical study of plasma urotensin Ⅱ in patients with coronary heart disease

FANG Shi-hu¹, LI Zhi-liang¹, WU Hong-chao¹, TANG Chao-shu², LU Qing¹, LIU Hai-chao¹, YAN Quan-neng¹

1. 第一军医大学珠江医院心血管内科, 广东, 广州, 510282;
2. 北京大学第一医院心血管研究所, 北京, 100034

Online:2004-05-20 Published:2004-05-20

摘要/Abstract

摘要： 目的探讨血管活性物质尾加压素Ⅱ(UⅡ)在冠心病患者体内的表达及其变化。方法采用放射免疫法测定50例冠心病患者及20例健康体检者的血浆UⅡ的水平。结果 (1)健康对照组静脉血浆UⅡ含量为3.70±1.30 pg/ml,冠心病患者的血浆UⅡ含量为1.61±1.02 pg/ml,两者有统计学差异(P=0.000)。冠心病患者中稳定性心绞痛者血浆UⅡ含量为2.62±1.20 pg/ml,不稳定心绞痛者UⅡ含量为1.39±0.80 pg/ml,急性心肌梗死者UⅡ含量为1.04±0.45 pg/ml,3组之间有显著性差异(P=0.004)。(2)冠心病患者中冠脉血管有闭塞组静脉血浆UⅡ含量为1.29±1.02 pg/ml,单纯狭窄组UⅡ含量为1.76±1.00 pg/ml,两者无统计学差异(P=0.131)。(3)经皮腔内冠状动脉成型术(PTCA)及支架植入术后,出现再狭窄患者组血浆UⅡ含量为2.28±0.94 pg/ml,而其他病人的血浆UⅡ含量为1.40±0.96 pg/ml,两者有统计学差异(P=0.008)。(4) PTCA治疗前后,股动脉血浆UⅡ的含量分别为1.18±1.14、2.22±1.77 pg/ml,两者有统计学差异(P=0.001)。结论 UⅡ可能参与了冠心病的发病;在PTCA治疗后出现支架内再狭窄中可能起作用。

Abstract: Objective To investigate the changes in plasma urotensin Ⅱ(UⅡ) expression levels in patients with coronary heart disease (CHD). Methods Plasma UⅡ levels in 50 CHD patients with coronary stenosis indicated by coronary angiography and 20 healthy subjects were determined by radio immunoassay. Results Venous plasma UⅡ levels were significantly lowered in CHD patients in comparison with tthe healthy subjects (1.61±1.02 pg/ml vs 3.70±1.30 pg/ml, P=0.000). In the CHD patient group, significantly differences were noted in the UⅡ levels between patients with stable angina (2.62±1.20 pg/ml), unstable angina (1.39±0.80 pg/ml) and acute myocardial infarction (AMI, 1.04±0.45 pg/ml, P=0.004). CHD patients with coronary artery occlusion and those with only coronary stenosis had comparable venous plasma UⅡ levels (1.29±1.02 pg/ml vs 1.76±1.00 pg/ml, P=0.131), whereas the patients with restenosis after percutaneous transluminal coronary angioplasty (PTCA) had higher UⅡ levels than the other subjects in the CHD patient group (2.28±0.94 pg/ml vs 1.40±0.96 pg/ml, P=0.008), and the femoral plasma UⅡ levels were significantly elevated after PTCT, increasing from 1.18±1.14 pg/ml to a postoperative level of 2.22±1.77 pg/ml (P=0.001). Conclusion UⅡ might play a role in the pathophysiological process of CHD and can be involved in the restenosis after angioplasty.

中图分类号:

方石虎¹, 李志樑¹, 吴宏超¹, 唐朝枢², 陆青¹, 刘海潮¹, 严全能¹. 冠心病患者血浆尾加压素Ⅱ的临床研究[J]. 南方医科大学学报, 2004, 24(05): 563-565.

FANG Shi-hu¹, LI Zhi-liang¹, WU Hong-chao¹, TANG Chao-shu², LU Qing¹, LIU Hai-chao¹, YAN Quan-neng¹. Clinical study of plasma urotensin Ⅱ in patients with coronary heart disease[J]. Journal of Southern Medical University, 2004, 24(05): 563-565.

参考文献

[1] 宋福春,陈爱华,唐晓明,等.血小板内皮细胞粘附因子基因多态性与冠心病的关系[J].第一军医大学学报,2003,23(2):156-8.Song FC, Chen AH, Tang XM, et al. Association ofplatelet endothelial cell adhesion molecule-1 gene polymorphism with coronary heart disease [J]. J First Mil Med Univ/Di Yi Jun Yi Da Xue Xue Bao, 2003, 23(2): 156-8.
[2] 欧阳伟,何国荣,刘金华.冠状动脉疾病危险因素与201TI心肌灌注显像的相关性研究[J].第一军医大学学报,2002,22(12):1123-5.Ouyang W, He GR, Liu JH. Relationship between risk factors for coronary artery disease and thallium-201 myocardial scintigraphy[J]. J First Mil Med Univ/Di Yi Jun Yi Da Xue Xue Bao, 2002, 22(12): 1123-5.
[3] 陈允钦,尹恝,张暋,等.冠心病患者血清β-脂蛋白谱的特点[J].第一军医大学学报,2003,23(7):740-2.Chen YQ, Yin J, Zhang M, et al. Features of serum beta-lipoproteinelectrophoretogram in patients with coronary heart disease [J]. J First Mil Med Univ/Di Yi Jun Yi Da Xue Xue Bao, 2003, 23 (7):740-2.
[4] 钟萍,李志樑.人尾加压素Ⅱ的心血管调节作用[J].第一军医大学学报,2002,22(6):566-8.Zhong P, Li ZL. Regulative effect of human urotensin- Ⅱ on cardiovascular system[J]. J First Mil Med Univ/Di Yi Jun Yi Da Xue Xue Bao, 2002,22(6): 566-8.
[5] Bern HA, Pearson D, Larson BA, et al. Neurohormones from fish tails: the caudal neurosecretory system I. "Urophysiology" and the caudal neurosecretory system of fishes [J]. Recent Prog Horm Res,1985, 41(5): 533-52.
[6] Coulouarn Y, Lihrmann I, Jegou S, et al. Cloning of the cDNA encoding the urotensin Ⅱ precursor in frog and human reveals intense expression of the urotensin Ⅱ gene in motoneurons of the spinal cord[J]. Proc Natl Acad Sci USA, 1998, 95(26): 15803-8.
[7] Ames RS, Sarau HM, Chambers JK, et al. Human urotensin- Ⅱ is a potent vasoconstrictor and agonist for the orphan receptor GPR14 [J]. Nature, 1999, 401(6750): 282-6.
[8] Douglas SA, Ohlstein EH. Human urotensin- Ⅱ, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease [J]. Trends Cardiovasc Med, 2000, 10(6): 229-37.
[9] Katano Y, Ishihata A, Aita T, et al. Vasodilator effect ofurotensin Ⅱ, one of the most potent vasoconstricting factors, on rat coronary arteries[J]. Eur J Pharmacol, 2000, 402(1-2): R5-7.
[10] Gray GA, Jones MR, Sharif I, et al. Human urotensin Ⅱ increases coronary perfusion pressure in the isolated rat heart: potentiation by nitric oxide synthase and cyclooxygenase inhibition [J]. Life Sci,2001, 69(2): 175-80.
[11] Watanabe T, Pakala R, Katagiri T, et al. Synergistic effect ofurotensin Ⅱ with mildly oxidized LDL on DNA synthesis in vascular smooth muscle cells[J]. Circulation, 2001, 104(1): 16-8.
[12] Meyers D, Galbraith A J, Bett N, et al. Elevated plasma levels of human urotensin- Ⅱ immunoreactivity in congestive heart failure[J].Am J Physiol Heart Circ Physiol, 2003, 285(4): 1576-81.
[13] 钟萍,李志梁,吴宏超,等.充血性心力衰竭患者血浆尾加压素Ⅱ变化的临床研究[J].第一军大学学报,2003,23(2):121-3.Zhong P, Li ZL, Wu HC, et al. Clinical study of changes of urotensin Ⅱ in patients with congestive heart failure[J]. J First Mil Med Univ/Di Yi Jun Yi Da Xue Xue Bao, 2003, 23(2): 121-3.
[14] 涂晓文,刘映峰,李志樑,等.尾加压素Ⅱ在冠状动脉中的表达与冠状动脉粥样硬化[J].第一军医大学学报,2003,23(6):572-4.Tu XW, Liu YF, Li ZL, et al. Expression of urotensin Ⅱ in human coronary artery and coronary atherosclerosis [J]. J First Mil Med Univ/Di Yi Jun Yi Da Xue Xue Bao, 2003, 23(6): 572-4.